Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Analysis: Understanding The Drivers Behind 13.4% CAGR Through 2030 Growth
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Poised To Hit $1.49 Billion By 2030 With A 13.4% CAGR
The multicancer early detection deoxyribonucleic acid (DNA) blood tests market has experienced rapid growth recently. It is projected to expand from $0.79 billion in 2025 to $0.9 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.2%. Historically, this growth has been driven by increasing global cancer incidence and mortality rates, the limited effectiveness of late-stage cancer diagnosis methods, the growing adoption of genomic sequencing technologies in oncology research, the expansion of centralized cancer diagnostic laboratories, and rising awareness of early cancer screening benefits among healthcare providers.
The multicancer early detection deoxyribonucleic acid (DNA) blood tests market is projected to experience substantial expansion in the coming years. This market is anticipated to reach $1.49 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This growth over the forecast period stems from several factors, including developments in multi-cancer early detection liquid biopsy techniques, increased incorporation of AI-based genomic interpretation systems, wider acceptance of personalized and precision oncology screening initiatives, the proliferation of preventive healthcare programs and population screening directives, and increased capital allocation for biomarker discovery and cancer genomics research. Key trends for this period encompass a greater uptake of liquid biopsy-based multi-cancer screening for prompt diagnosis, expanded application of circulating tumor DNA sequencing for non-invasive cancer assessment, deeper integration of AI-powered biomarker interpretation in foreseeing cancer risk, the broadening of preventive oncology screening programs across populations, and an escalating preference for less intrusive blood-based cancer tests compared to conventional biopsy procedures.
Get A Free Sample Report With In-Depth Market Insights:
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Growth Drivers: What’s Behind The Acceleration?
The increasing prevalence of cancer worldwide is anticipated to drive the expansion of the multicancer early detection DNA blood tests market moving forward. Cancer is a set of illnesses characterized by uncontrolled cell growth and spread, capable of invading nearby tissues and, in advanced stages, spreading to other body parts. The global incidence of cancer is rising as health systems report higher rates and improved screening and detection technologies identify more cases earlier. Multicancer early detection DNA blood tests support this growing prevalence by offering non-invasive, blood-based screening solutions that enable the early identification of various cancer types through circulating tumor DNA analysis, thereby enhancing early diagnosis and patient outcomes. For example, in April 2024, data from the International Agency for Research on Cancer indicated nearly 20 million new cancer cases and close to 10 million deaths from cancer in 2022. Demographics-based forecasts predict that the annual number of new cancer cases will reach 35 million by 2050, representing a 77% increase from 2022. Therefore, the increasing global prevalence of cancer is propelling the growth of the multicancer early detection DNA blood tests market. The rising awareness of preventive healthcare is expected to propel the growth of the multicancer early detection DNA blood tests market going forward. Preventive healthcare encompasses medical practices and strategies focused on preventing disease, enabling early diagnosis, and maintaining health to lessen the risk of severe illnesses and improve long-term health outcomes. Awareness of preventive healthcare is increasing due to growing public health campaigns, expanding access to healthcare information, and a rising emphasis on early disease detection and personalized medicine. Multicancer early detection DNA blood tests support preventive healthcare by offering non-invasive and convenient screening methods that enable the early identification of multiple cancer types through circulating tumor DNA analysis, helping improve treatment outcomes and survival rates. For instance, in January 2025, according to the Prevent Cancer Foundation, participation in preventive cancer screening programs increased by 9.3% in 2024 compared to the previous year, reflecting growing public awareness and adoption of early detection practices. Therefore, the rising awareness of preventive healthcare is driving the growth of the multicancer early detection DNA blood tests market.
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Breakdown By Product Type And Application
The multicancer early detection deoxyribonucleic acid (dna) blood tests market covered in this report is segmented –
1) By Test Type: Pan-Cancer Minimal Residual Disease Early Detection Tests, Targeted Multi-Cancer Panels, Single-Cancer Deoxyribonucleic Acid Blood Tests
2) By Technology: Circulating Cell-Free Deoxyribonucleic Acid Methylation Profiling, Circulating Cell-Free Deoxyribonucleic Acid Mutation Analysis, Fragmentomics, Multi-Analyte Approaches, Other Epigenomic Approaches
3) By Sample Type: Blood, Plasma, Urine
4) By Application: Asymptomatic Population Screening, Diagnostic Support, Cancer Recurrence Monitoring
5) By End Users: Reference Laboratories, Hospital Laboratories, Clinics, Direct-To-Consumer Users
Subsegments:
1) By Pan-Cancer Minimal Residual Disease Early Detection Tests: Solid Tumor Detection Panels, Hematological Cancer Detection Panels, Early Stage Cancer Screening Panels, Late Stage Cancer Detection Panels, Whole Body Cancer Screening Tests
2) By Targeted Multi-Cancer Panels: Organ Specific Cancer Panels, High Risk Population Screening Panels, Genetic Marker Based Panels, Epigenetic Marker Based Panels, Combination Biomarker Panels
3) By Single-Cancer Deoxyribonucleic Acid Blood Tests: Breast Cancer Detection Tests, Lung Cancer Detection Tests, Colorectal Cancer Detection Tests, Prostate Cancer Detection Tests, Liver Cancer Detection Tests
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies operating in the multicancer early detection DNA blood tests market are focusing on developing innovative solutions, such as advancements in cell-free DNA (cfDNA) and methylation-based sequencing technologies, to address the increasing demand for early, non-invasive, and multi-cancer screening solutions. Cell-free DNA-based testing involves analyzing fragmented DNA released into the bloodstream by tumor cells, making it possible to detect multiple cancers from a single blood draw, unlike traditional diagnostic approaches that rely on invasive biopsies or organ-specific imaging techniques. For instance, in March 2025, Gene Solutions, a Vietnam-based biotechnology company, introduced an advanced multi-cancer early detection blood test crafted for population-scale screening. The test employs cfDNA analysis combined with machine learning algorithms to identify cancer-specific genomic and epigenomic signatures across numerous cancer types. It facilitates early-stage cancer detection with high predictive accuracy while minimizing false positives, making it suitable for routine health screening. Additionally, the test incorporates tumor origin prediction technology to help identify the likely source of cancer for further diagnosis and is designed to improve accessibility to early cancer detection, particularly in regions with limited screening infrastructure.
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Top Companies Driving Competitive Growth
Major companies operating in the multicancer early detection deoxyribonucleic acid (dna) blood tests market are Thermo Fisher Scientific Inc., Prenetics Global Limited, Eurofins Scientific Inc., SeekIn Inc., VolitionRx Limited, Myriad Genetics Inc., Guardant Health, Freenome Holdings Inc., GENECAST Biotechnology Co. Ltd., Burning Rock Biotech Limited, Geneseeq Technology Inc. , Quibim S. L., 1drop Inc., Bioneer Corporation, CellMax Life, Datar Cancer Genetics, Laboratory for Advanced Medicine Inc., Harbinger Health Inc., Norgen Biotek Corp., Singlera Genomics Inc., Elypta AB, StageZero Life Sciences, INOVIQ, AnPac Bio-Medical Science, EarlyDiagnostics, Micronoma
View The Full Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Report:
Multicancer Early Detection Deoxyribonucleic Acid (DNA) Blood Tests Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the multicancer early detection DNA blood tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multicancer early detection deoxyribonucleic acid (DNA) blood tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
